GET DAILY SIGNALSDoximity (DOCS) Delivers Q2 Revenue Beat but Shares Slip -6.7% on Margin Pressures
Key Takeaways
- Doximity reported fiscal second quarter 2027 revenue of $174.5 million, up 3.6% year over year and ahead of the consensus estimate of roughly $171.1 million.
- Adjusted earnings per share (EPS) of $0.36 came in line with analyst expectations of about $0.35.
- Adjusted EBITDA reached $88.9 million, a 50.9% margin, but GAAP operating margin narrowed to 25.2% from 37.8% a year ago as AI compute costs climbed.
- Management modestly raised full-year revenue guidance to about $680.5 million at the midpoint.
- Billings of $165.7 million grew 9.5% year over year, yet shares slipped roughly 6.7% after the report amid margin concerns.
Putting the Quarter in Perspective
Doximity's fiscal second quarter 2027 results, for the period ended September 30, 2026, arrived at a pivotal moment for the medical professional network. The company has been aggressively investing in artificial intelligence while navigating a softer market for digital pharmaceutical advertising, its core revenue driver. I was watching closely to see whether accelerating AI compute spending would pressure a historically high-margin business, and whether demand from health systems could offset weakness in pharma advertising. The report mattered because it tested Doximity's ability to preserve profitability during a strategic transition from a high-margin advertising model toward subscription-based AI tools for clinicians and health systems.
The Numbers Breakdown
Doximity reported revenue of $174.5 million for its fiscal second quarter of 2027, up 3.6% year over year and ahead of the consensus estimate of roughly $171.1 million. Adjusted EPS came in at $0.36, essentially in line with the consensus of $0.35. On a non-GAAP basis, adjusted EBITDA totaled $88.9 million, beating the consensus estimate of about $81.5 million and reflecting a 50.9% adjusted EBITDA margin.
Profitability under GAAP told a more pressured story: operating margin narrowed to 25.2%, down sharply from 37.8% in the year-ago quarter, driven by higher AI compute costs. Free cash flow margin improved to 52.3% from 25.3% in the prior quarter. Billings, a forward-looking measure of invoiced activity, rose 9.5% year over year to $165.7 million. Management raised its full-year revenue guidance to about $680.5 million at the midpoint, while issuing full-year EBITDA guidance of approximately $321 million at the midpoint. CEO Jeff Tangney highlighted record engagement and noted that more than 190 health systems have adopted the company's AI suite. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
The market's response to Doximity's report was notably cautious. Despite a top-line beat and in-line adjusted EPS, shares fell roughly 6.7% to about $31.01 immediately after the release. The decline reflected investor unease over the meaningful compression in GAAP operating margin and the softer near-term demand in digital pharma advertising. The divergence between solid adjusted profitability and rising AI compute costs suggests the market is focused on the sustainability of Doximity's margin profile as AI usage ramps up. Sentiment heading into and following the print remained guarded, with investors weighing the company's long-term AI opportunity against the near-term cost of funding that expansion. From what I see, this reaction highlights how sensitive the valuation remains to any sign of margin erosion.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will likely focus on whether Doximity can balance its AI investment cycle with margin discipline. Management's raised revenue guidance signals confidence in demand, but the primary question is whether AI compute costs will continue to outpace revenue growth and further compress operating margins.
Several factors are worth monitoring. First, the trajectory of billings growth will offer a read on future subscription revenue, particularly as more health systems adopt the AI suite and products such as UpToDate and DoseCheck. Second, the state of the digital pharma advertising market remains a swing factor, given management's previously noted softness and limited visibility in that segment.
Finally, watch for updates on customer retention and the net revenue retention rate, as well as how share repurchases interact with the higher stock-based compensation expected in fiscal 2027. These elements will help determine whether the company's profitability can stabilize even as it prioritizes long-term AI expansion. I’m watching this closely as the transition plays out.
Using AI Tools in My Research Process
In my analysis of earnings-driven moves like this one, I often turn to Tickeron’s AI-powered tools to gain additional perspective on comparable names in healthcare technology. One resource that has proven useful is the AI Screener, which allows filtering by technical patterns, fundamentals, and AI-driven signals to identify potential opportunities more efficiently. It helps surface ideas without replacing core fundamental work, and I find it particularly handy when comparing margin trends across peers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DOCS sees MACD Histogram crosses below signal line
DOCS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 30, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 35 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 81%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for DOCS moved out of overbought territory on October 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 21 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 56 cases where DOCS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DOCS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
DOCS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on DOCS as a result. In 59 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The 50-day moving average for DOCS moved above the 200-day moving average on October 14, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +3.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where DOCS advanced for three days, in 210 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 123 of 178 cases where DOCS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. DOCS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.746) is normal, around the industry mean (4.886). P/E Ratio (38.522) is within average values for comparable stocks, (13.782). Projected Growth (PEG Ratio) (0.590) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (7.776) is also within normal values, averaging (6.065).
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DOCS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement